EPA, FDA and USDA Issues Updates to the Joint Regulatory Plan for Biotechnology

Contact Information: EPA Press Office ( press@epa.gov )

WASHINGTON  – Today, May 8, 2024, in response to President Biden’s Executive Order 14081, “Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy,” the U.S. Environmental Protection Agency, the U.S. Food and Drug Administration and the U.S. Department of Agriculture have  developed a plan  to update, streamline and clarify their regulations and oversight mechanisms for products of biotechnology.

The plan helps meet the President’s goals of ensuring public confidence in the biotechnology regulatory system and improving its transparency, predictability, coordination and efficiency. Through engagement with developers and stakeholders, as well as horizon scanning for novel biotechnology products, the agencies worked collaboratively to develop a cohesive plan. The plan incorporates processes and timelines to implement regulatory reform, such as identifying guidance and regulations to update, streamline, or clarify, and identifying the potential need for new guidance or regulations. The plan supports a whole-of-government approach to the regulation of biotechnology products.

The agencies have identified five major areas of biotechnology product regulation where these actions will focus:

  1. Modified plants
  2. Modified animals
  3. Modified microorganisms
  4. Human drugs, biologics and medical devices
  5. Cross-cutting issues

EPA, the FDA and USDA intend to implement the following joint efforts:

  • Clarify and streamline regulatory oversight for genetically engineered plants, animals and microorganisms;
  • Update and expand their information sharing through an MOU to improve and broaden communication and coordination of oversight of modified microbes; and
  • Undertake a pilot project focused on modified microbes to explore and consider the feasibility and costs of developing a web-based tool that informs developers about which agency may regulate a given product category.

The federal government established the Coordinated Framework for the Regulation of Biotechnology in 1986 and most recently updated it in 2017. It describes the comprehensive federal regulatory policy for ensuring the safety of biotechnology products, including how EPA, the FDA and USDA share responsibility for regulating many of the products of biotechnology in the United States. The Executive Order directs the three agencies to improve how they implement the Coordinated Framework.   

In response to the Executive Order, the three regulatory agencies, in consultation with the Office of Science and Technology Policy, issued a Request for Information to the public to solicit information on regulatory ambiguities, gaps, uncertainties or inefficiencies in the Coordinated Framework. The agencies received 88 distinct public comments, including a sign-on letter from over 6,000 members from biotechnology developers, producers, manufacturers, non-governmental organizations and academia. The agencies will continue to engage with all interested stakeholders as they implement the plan.

Visit the  Unified Website for Biotechnology Regulation  for additional information on modernizing the regulatory system for biotechnology products and Executive Order 14081.

By Maria Thacker Goethe May 16, 2025
Georgia is home to a dynamic and fast-growing life sciences industry—built on bold ideas, scientific risk-taking, and an unwavering commitment to improving patient outcomes. That progress depends on smart, forward-looking policies that support innovation, investment, and access to care. The Most Favored Nation (MFN) policy outlined in this week’s Executive Order threatens to undermine those goals. By tying U.S. drug reimbursement to artificially low prices set by foreign governments, MFN would effectively import price controls from systems that frequently delay—or outright deny—patient access to new therapies. This policy would have real and damaging consequences: stifling innovation, weakening our national leadership in biomedical R&D, and jeopardizing the survival of early-stage biotech companies that form the backbone of Georgia’s life sciences economy. The cost of these short-sighted policies is not theoretical. It means fewer life-saving therapies making it to market—especially for patients with rare, complex, or life-threatening diseases. Studies have repeatedly shown that countries with strict price controls suffer from slower access to breakthrough treatments, if they receive them at all. Georgia Life Sciences urges the Administration and Congress to reject policies that compromise patient care and biomedical progress. Instead, we must work together on balanced solutions that lower out-of-pocket costs for patients while preserving America’s innovation ecosystem. We remain committed to partnering with policymakers to ensure patients in Georgia—and across the country—continue to benefit from the scientific advances our sector delivers every day.
By Sheran Brown May 15, 2025
Georgia Life Sciences Designates Augusta as Newest BioReady® Community
By Sheran Brown May 14, 2025
Strength in Science. Power in Numbers. In a year filled with political uncertainty, one thing is clear: Georgia’s life sciences industry must speak with a united voice. From federal policy shifts to state-level regulatory changes, the decisions being made are directly impacting funding, innovation pipelines, workforce policy, and healthcare access. If we don’t shape the narrative, someone else will. That’s why now is the time to join Georgia Life Sciences . Why Join Now? Policy Advocacy : Amplify your voice where it matters—at the Capitol and in Congress. Visibility & Influence: Be recognized as part of Georgia’s innovation backbone. Networking & Growth : Tap into a thriving ecosystem of researchers, entrepreneurs, investors, and executives. Collective Impact: The greater our numbers, the stronger our position. The Stakes Are High As political tides shift, science needs champions—not just in the lab, but at the table where decisions are made. Your membership isn’t just a badge—it’s a signal that science will not sit on the sidelines. Join Today. Lead Tomorrow. Membership applications received by June 30 qualify for a 50% discount on first year dues . Applies to new memberships only.
MORE POSTS